Hoya Group, PENTAX of America, and MAGENTIQ EYE to Establish Distribution Collaboration for U.S. Market

Saturday, May 18, 2024

HOYA Group's subsidiary, PENTAX of America, and MAGENTIQ-EYE, an AI medical device firm, have announced their intention to collaborate in the realm of AI in Gastroenterology.

Pending field trials and customer demonstrations over the coming months, the companies aim to solidify an agreement to distribute MAGENTIQ-COLO™, an AI-assisted lesion detection device, in the U.S. starting October 1st, 2024.

The system, heralded for its advanced capabilities in detecting gastrointestinal lesions during colonoscopies, will be showcased at the upcoming Digestive Disease Week (DDW) in Washington D.C., U.S.A.

MAGENTIQ-COLO™, having undergone successful validation in an international multicenter, randomized, controlled trial (RCT) involving 950 patients across 10 hospitals in Europe, the United States, and Israel, is poised to set new standards in endoscopic AI.

"Thrilled to introduce the MAGENTIQ-COLO™ device to the GI community in the U.S. This collaboration, alongside PENTAX Medical's product lineup, promises to offer a sophisticated solution in colonoscopy, furthering our efforts in colorectal cancer prevention," states, President of PENTAX of America, Inc.

"Partnering with PENTAX Medical marks a significant milestone for us, providing an avenue to bring our groundbreaking product to the U.S. market, ultimately benefiting both physicians and patients and potentially saving lives," adds Founder & CEO of MAGENTIQ-EYE.


Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital Congress